65908 Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices 

fundings with respect to: (1) Advancing 

scientific accomplishments involving 

innovative, clinically relevant, and 

multidisciplinary research on type 1 

diabetes; (2) developing resources or 

reagents useful for type 1 diabetes 

research; and (3) increasing the number 

and quality of type 1 diabetes 

investigators. The responses will 

provide valuable information 

concerning how the funds have 

facilitated research as intended by these 

Acts of the Congress. The results will 

also help determine how research 

progress from these special 

congressional initiatives fits within the 

continuum of diabetes research, and 

how these funds have contributed to the 

field of type 1 diabetes research and 

NIH efforts to combat this challenging 

health problem. Information from this 

study will aid in evaluation of the 

process by which the research goals for 

use of the special type 1 diabetes funds 

have been developed and are being 

pursued. Responses already collected 

from this survey were analyzed as part 

of an interim program assessment that 

was published by the NIDDK in April, 

2003 http://www.niddk.nih.gov/federal/ 

planning/type 1_specialfund/. This 

revised survey will contribute to a 

statutorily mandated report, due to the 

Congress on January 1, 2007, evaluating 

the process and efforts under this 

program and assessing research 

initiatives funded by these Act of 

Congress. Frequency of Response: The 

survey will require a one time response; 

though, respondents may be contacted 

again in the event of future 

congressionally mandated reports on the 

use of the special type 1 diabetes 

research funds. Affected Public: 

Research scientists who received the 

special funds about which the Congress 

has mandated in law the requirements 

for an evaluation report. Type of 

Respondents: Laboratory and clinical 

investigators who have received support 

from the special type 1 diabetes funds 

provided under the laws previously 

cited. The annual reporting burden is as 

follows: Estimated number of 

respondents: 500; Estimated Number of 

Responses per Respondent: 1; Average 

Burden Hours per Response: 1; and 

Estimated Total Burden Hours 

Requested: 500. The annualized total 

cost to respondents is estimated at: 

$25,000. It is expected that the 

respondents will be contacted and will 

return their responses via electronic 

mail. These measures will reduce the 

burden on the respondents and the 

overall costs of administering the study. 

Respondents will be asked to answer no 

more than sixteen questions, one-third 

of which will be answered with ‘‘yes’’

or ‘‘no’’ or a one-word response. There 

are no Capital Costs, Operating Costs or 

Maintenance Costs to report. 

Request For Comments 

Written comments and/or suggestions 

from the public and affected agencies 

are invited on one or more of the 

following points: (1) Whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) The accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions sued; (3) 

Ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Ways to minimize the 

burden of the collection of information 

on those who are to respond, including 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

Direct Comments to OMB 

Written comments and/or suggestions 

regarding the item(s) contained in this 

notice, especially regarding the 

estimated public burden and associated 

response time, should be directed to the: 

Office of Management and Budget, 

Office of Regulatory Affairs, New 

Executive Office Building, Room 10235, 

Washington, DC 20503, Attention: Desk 

Officer for NIH. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and instruments, contact: Dr. 

Shefa Gordon, Presidential Management 

Fellow, Office of Scientific Program and 

Policy analysis, NIDDK, NIH, Building 

31, Room 9A31, 9000 Rockville Pike, 

Bethesda, MD 20892, or call non-tollfree number (301) 496–6623 or e-mail 

your request, including your address, to: 

gordonshefa@mail.nih.gov. 

Comments Due Date 

Comments regarding this information 

collection are best assured of having 

their full effect if received within 30 

days of the date of this publication. 

Dated: October 19, 2005. 

Barbara Merchant, 

Executive Officer, NIDDK. 

[FR Doc. 05–21649 Filed 10–31–05; 8:45 am] 

BILLING CODE 4140–01—M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of Biotechnology Activities, 

Office of Science Policy, Office of the 

Director; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the second meeting of 

the National Science Advisory Board for 

Biosecurity (NSABB). 

Under authority 42 U.S.C. 217a, 

Section 222 of the Public Health Service 

Act, as amended, the Department of 

Health and Human Services established 

NSABB to provide advice, guidance and 

leadership regarding federal oversight of 

dual-use research, defined as biological 

research with legitimate scientific 

purposes that could be misused to pose 

a biological threat to public health and/ 

or national security. 

The meeting will be open to the 

public, however, pre-registration is 

strongly recommended due to space 

limitations. Persons planning to attend 

should register online at http:// 

www.biosecurityboard.gov/meetings.asp 

or by calling The Hill Group (Contact: 

A.J. Bownas) at 301–897–2789, ext. 100. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

indicate these requirements upon 

registration. 

Name of Committee: National Science 

Advisory Board for Biosecurity. 

Date: November 21, 2005. 

Open: 9 a.m. to 6 p.m. 

Agenda: Presentations and discussions 

regarding: (1) Criteria for defining dual-use 

research in the life sciences; (2) the role of 

a code of conduct for the life sciences; (3) 

communication of dual use research; (4) 

international perspectives on dual use 

research; (5) public comments; and (6) and 

other business of the Board. 

Place: The National Institutes of Health, 

Building 31, 6C—Room 10, Bethesda, 

Maryland. 

Contact Person: Allison Chamberlain, 

NSABB Program Assistant, 6705 Rockledge 

Drive, Bethesda, Maryland 20892, (301) 402–

3090. 

This meeting will also be webcast. The 

draft meeting agenda and other information 

about NSABB, including information about 

access to the webcast and pre-registration, 

will be available at http:// 

www.biosecurityboard.gov/meetings.asp. 

Any member of the public interested in 

presenting oral comments at the meeting may 

notify the Contact Person listed on this notice 

at least 10 days in advance of the meeting. 

Interested individuals and representatives of 

an organization may submit a letter of intent, 

a brief description of the organization 

Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices 65909 

represented and a short description of the 

oral presentation. Only one representative of 

an organization may be allowed to present 

oral comments. Both printed and electronic 

copies are requested for the record. In 

addition, any interested person may file 

written comments with the committee. All 

written comments must be received by 

November 7, 2005 and should be sent via email to nsabb@od.nih.gov with ‘‘NSABB 

Public Comment’’ as the subject line or by 

regular mail to 6705 Rockledge Drive, Suite 

750, Bethesda, MD 20892, Attention Allison 

Chamberlain. The statement should include 

the name, address, telephone number and, 

when applicable, the business or professional 

affiliation of the interested person: 

Dated: October 20, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–21661 Filed 10–31–05; 8:45 am] 

BILLING CODE 4140-01-M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel. RFA: 

CA06–502 ‘‘AIDS Malignancy Clinical Trials 

Consortium.’’

Date: November 30, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ramada Inn Rockville, 1775 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Joyce C. Pegues, PhD., 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd. 7149, 

Bethesda, MD 20892. 301/594–1286. 

peguesj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: October 20, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–21646 Filed 10–31–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel 

Review of Research Project (R01) 

Applications 

Date: November 30, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Loews Annapolis Hotel, 126 West 

Street, Annapolis, MD 21401. 

Contact Person: Katherine M. Malinda, 

PhD, Scientific Review Administrator, 

Review Branch, Division of Extramural 

Affairs, National Heart, Lung, and Blood 

Institute, National Institutes of Health, 6701 

Rockledge Drive, Room 7198, Bethesda, MD 

20892, 301/435–0297. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel 

Review of Research Project (RO1) 

Applications 

Date: November 30, 2005. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Bethesda, MD 

20892, (Telephone Conference Call). 

Contact Person: Patricia A. Haggerty, PhD, 

Scientific Review Administrator, National 

Heart, Lung, and Blood Institute/NIH, 

Clinical Studies & Training Studies Rev. 

Grp., Division of Extramural Affairs/Section 

Chief, 6701 Rockledge Drive, Room 7194, 

Bethesda, MD 20892, 301/435–0288. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: October 20, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–21656 Filed 10–31–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the Sleep 

Disorders Research Advisory Board. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting: 

Name of Committee: Sleep Disorders 

Research Advisory Board. 

Date: December 6, 2005. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To discuss sleep research and 

education priorities and programs. 

Place: National Institutes of Health, 

Natcher Building, Conference Room D, 

Bethesda, MD 20892. 

Contact Person: Carl E Hunt, MD, Director, 

National Center on Sleep Disorders Research, 

National Heart, Lung, and Blood Institute, 

National Institutes of Health, 6705 Rockledge 

Drive, Room 6022, Bethesda, MD 20892, 301/ 

435–0199. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. This statement should include 

the name, address, telephone number and 

when applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

into the building by non-governmental 

employees. Persons without a government 

I.D. will need to show a photo I.D. and signin at the security desk upon entering the 

building. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nhlbi.nih.gov/meetings/index.htm, 

where an agenda and any additional